Kyntra Bio, Inc. (KYNB) Financials

KYNB Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 109.6 million 118.9 million
Dec. 31, 2025 119.6 million 115.1 million
Sept. 30, 2025 137.0 million 119.5 million
June 30, 2025 178.1 million 359.1 million

KYNB Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -13.9 million 1.2 million
Dec. 31, 2025 -18.3 million 1.2 million
Sept. 30, 2025 -1.9 million ?
June 30, 2025 12.7 million 1.9 million

KYNB Net Income

No data available :(

KYNB Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 87.2 million - -
Dec. 31, 2025 89.0 million - -
Sept. 30, 2025 118.0 million 19.5 million -
June 30, 2025 23.4 million - -

KYNB Shares Outstanding

No data available :(

KYNB Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 7.6 million 5.9 million -
Dec. 31, 2025 - 7.3 million 7.3 million -
Sept. 30, 2025 8999 1.2 million 5.1 million -
June 30, 2025 13000 5.9 million 6.8 million -

KYNB Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 3.7 million -
Dec. 31, 2025 1.3 million -
Sept. 30, 2025 1.1 million 134000
June 30, 2025 1.3 million 306000

KYNB Revenue by Segment

Graph available only for paid members. Upgrade to see it.

KYNB

Price: $6.68

52 week price:
4.85
12.60

Earnings Per Share: -12.85 USD

P/E Ratio: -0.54

Exchange: NGM

Sector: Healthcare

Industry: Medical - Pharmaceuticals

Market Capitalization: 29.1 million

Links: